A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC).

被引：11
|
作者：
Sangro, Bruno [1 ,2 ]
Harding, James J. [3 ]
Johnson, Matthew [4 ]
Palmer, Daniel H. [5 ,6 ]
Edeline, Julien [7 ]
Abou-Alfa, Ghassan K. [8 ]
Cheng, Ann-Lii [9 ]
Decaens, Thomas [10 ]
El-Khoueiry, Anthony B. [11 ]
Finn, Richard S. [12 ]
Galle, Peter R. [13 ]
Park, Joong-Won [14 ]
Yau, Thomas [15 ]
Begic, Damir [16 ]
Shen, Yun [16 ]
Neely, Jaclyn [16 ]
Sama, Ashwin Reddy [16 ]
Kudo, Masatoshi [17 ]
机构：
[1] Clin Univ Navarra, Pamplona, Spain
[2] CIBEREHD, Pamplona, Spain
[3] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
[4] Indiana Univ Sch Med, Dept Radiol & Imaging Sci, Indianapolis, IN 46202 USA
[5] Univ Liverpool, Liverpool Expt Canc Med Ctr, Liverpool, Merseyside, England
[6] Clatterbridge Canc Ctr, Liverpool, Merseyside, England
[7] Ctr Eugene Marquis, Rennes, France
[8] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[9] Natl Taiwan Univ Hosp, Taipei, Taiwan
[10] Univ Grenoble Alpes, Dept Gastroenterol & Hepatol, INSERM, Grenoble, France
[11] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA
[12] UCLA, Geffen Sch Med, Los Angeles, CA USA
[13] Univ Med Ctr Mainz, Mainz, Germany
[14] Natl Canc Ctr, Ctr Liver Canc, Goyang, South Korea
[15] Univ Hong Kong, Hong Kong, Peoples R China
[16] Bristol Myers Squibb, Princeton, NJ USA
[17] Kindai Univ, Fac Med, Osaka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期
关键词：
D O I：
10.1200/JCO.2021.39.3_suppl.TPS349
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS349
引用
收藏
页数：2
相关论文
共 50 条
  • [1] CHECKMATE 067: A PHASE III RANDOMIZED DOUBLE-BLIND STUDY OF NIVOLUMAB (NIVO) MONOTHERAPY OR NIVO COMBINED WITH IPILIMUMAB (IPI) VERSUS IPI MONOTHERAPY IN PREVIOUSLY UNTREATED PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL)
    Wolchok, J. D.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Rutkowski, P.
    Grob, J. J.
    Cowey, C. L.
    Lao, C. D.
    Schadendorf, D.
    Ferrucci, P. F.
    Smylie, M.
    Dummer, R.
    Hill, A.
    Haanen, J.
    Maio, M.
    McArthur, G.
    Yang, A.
    Rollin, L.
    Horak, C.
    Larkin, J.
    Hodi, F. S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 68 - 68
  • [2] CheckMate 067: a phase III randomized double-blind study of nivolumab (NIVO) monotherapy or NIVO combined with ipilimumab (IPI) versus IPI monotherapy in previously untreated patients (pts) with advanced melanoma (MEL)
    Wolchok, J. D.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Rutkowski, P.
    Grob, J.
    Cowey, C. L.
    Lao, C. D.
    Schadendorf, D.
    Ferrucci, P. F.
    Smylie, M.
    Dummer, R.
    Hill, A.
    Haanen, J.
    Maio, M.
    McArthur, G.
    Yang, A.
    Rollin, L.
    Horak, C.
    Larkin, J.
    Hodi, F. S.
    ANNALS OF ONCOLOGY, 2015, 26 : 28 - 28
  • [3] Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial.
    Lencioni, Riccardo
    Llovet, Josep M.
    Han, Guohong
    Tak, Won-Young
    Yang, Jiamei
    Leberre, Marie-Aude
    Niu, Woody
    Nicholson, Kate
    Meinhardt, Gerold
    Bruix, Jordi
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [4] LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment
    Ogasawara, S.
    Llovet, J.
    El-Khoueiry, A.
    Vogel, A.
    Madoff, D.
    Finn, R.
    Ren, Z.
    Modi, K.
    Li, J.
    Siegel, A.
    Dubrovsky, L.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S124 - S125
  • [5] Transarterial chemoembolization (TACE) with or without lenvatinib (len) plus pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): Phase III LEAP-012 study
    Llovet, J.
    Finn, R. S.
    Ren, Z.
    Guo, Y.
    Han, G.
    Lin, H.
    Zheng, J.
    Ogasawara, S.
    Li, H.
    Kim, J. H.
    Zhao, H.
    Li, C.
    Madoff, D. C.
    Ghobrial, R. M.
    El-Khoueiry, A. B.
    Vogel, A.
    Peng, X.
    Mody, K.
    Dubrovsky, L.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2024, 35 : 1229 - 1229
  • [6] A multicenter pilot study of nivolumab (NIVO) with drug eluting bead transarterial chemoembolization (deb-TACE) in patients (pts) with liver limited hepatocellular carcinoma (HCC).
    Harding, James J.
    Erinjeri, Joseph Patrick
    Tan, Benjamin R.
    Reiss, Kim Anna
    Mody, Kabir
    Khalil, Daniel
    Yarmohammadi, Hooman
    Nadolski, Gregory
    Giardina, Joseph Daniel
    Capanu, Marinela
    Do, Richard K. G.
    Bradley, Mikaela
    Boussayoud, Chayma
    Valentino, Emily
    Merghoub, Taha
    Jarnagin, William R.
    Soulen, Michael C.
    Brown, Karen T.
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase II trial (IMMUNED)
    Schadendorf, D.
    Hassel, J. C.
    Fluck, M.
    Eigentler, T.
    Loquai, C.
    Berneburg, M.
    Gutzmer, R.
    Meier, F.
    Mohr, P.
    Hauschild, A.
    Becker, J. C.
    Menzer, C.
    Kiecker, F.
    Dippel, E.
    Simon, J-C.
    Conrad, B.
    Garbe, C.
    Koerner, S.
    Livingstone, E.
    Zimmer, L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [8] Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238)
    Weber, J.
    Mandala, M.
    Del Vecchio, M.
    Gogas, H.
    Arance, A. M.
    Cowey, L. C.
    Dalle, S.
    Schenker, M.
    Chiarion-Sileni, V.
    Marquez-Rodas, I.
    Grob, J-J.
    Butler, M.
    Middleton, M. R.
    Maio, M.
    Atkinson, V.
    Queirolo, P.
    de Pril, V.
    Qureshi, A.
    Larkin, J.
    Ascierto, P. A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] Nivolumab (NIVO) and drug eluting bead transarterial chemoembolization (deb-TACE): Preliminary results from a phase I study of patients (pts) with liver limited hepatocellular carcinoma (HCC)
    Harding, James J.
    Yarmohammadi, Hooman
    Reiss, Kim Anna
    Chou, Joanne F.
    Capanu, Marinela
    Do, Richard K. G.
    Khalil, Danny
    El Dika, Imane H.
    Giardina, Joseph Daniel
    Merghoub, Taha
    Jarnagin, William R.
    Nadolski, Gregory
    Erinjeri, Joseph Patrick
    Soulen, Michael C.
    Tan, Benjamin R.
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [10] LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC)
    El-Khoueiry, Anthony B.
    Llovet, Josep M.
    Vogel, Arndt
    Madoff, David C.
    Finn, Richard S.
    Ogasawara, Sadahisa
    Ren, Zhenggang
    Mody, Kalgi
    Li, Jerry J.
    Siegel, Abby B.
    Dubrovsky, Leonid
    Kudo, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
12345